刚果民主共和国的 Bundibugyo Ebola 疫情推进极快：WHO 宣布紧急状态后，只过了略多于 1 周，科学界就已锁定最有潜力的治疗与疫苗候选，并大致知道如何测试；但截至目前，仍没有任何获准用于这一株病毒的疫苗或治疗。现有可用方案主要是针对 Zaire Ebola 研发的工具，其中 remdesivir 与其口服版本 obeldesivir，以及由 Mapp Biopharmaceutical 开发、基于抗体鸡尾酒的疗法，已被 WHO、DRC 与 Africa CDC 列为优先测试项目。

疫情规模与地面现实正在拖慢科学进展：疑似病例接近 1,100 例、疑似死亡近 240 例，Tedros Adhanom Ghebreyesus 形容部分地区面临「疾病与冲突的灾难性碰撞」；援助人员与医疗设施遭到攻击，关于 Ebola 的错误资讯与对人道援助的不信任也十分普遍。这使得隔离感染者、追踪接触者这些基本工作都变得困难，更不用说临床试验。

科学上仍有理由保持审慎乐观：Bundibugyo 与 Zaire 的 glycoprotein 约有 70% 相似度，意味著某些 Zaire 疫苗或疗法可能对 Bundibugyo 有效；remdesivir 在 Zaire 病例的人体试验中表现平平，但实验室结果显示对 Bundibugyo 可能更强。全球准备度监测委员会指出，近 10 年健康危机后，preparedness 正被 pandemic risks、geopolitical instability 与 rapidly evolving information ecosystems 等新压力超越；在这场疫情中，科学进步与社会现实之间的落差已经成为决定成败的关键。

In the Democratic Republic of Congo’s fast-moving Bundibugyo Ebola outbreak, the scientific community has mobilized with unusual speed: a little more than 1 week after the WHO declared an emergency, experts had already narrowed down the most promising treatment and vaccine candidates and had a workable plan for testing them. Yet no vaccine or treatment is currently authorized for this strain. The main options on hand are tools developed for Zaire Ebola, including remdesivir, its oral version obeldesivir, and an antibody cocktail being developed by Mapp Biopharmaceutical, which the WHO, the DRC and Africa CDC have prioritized for testing.

The outbreak is colliding with severe on-the-ground constraints. Suspected cases are nearing 1,100 and suspected deaths are close to 240, while Tedros Adhanom Ghebreyesus said parts of the DRC face “a catastrophic collision of disease and conflict.” Aid workers and health facilities have been attacked, and misinformation about Ebola plus distrust of humanitarian help are widespread. That makes even basic tasks such as isolating patients and tracing contacts difficult, let alone running a clinical trial.

There are still scientific reasons for guarded optimism. The Bundibugyo and Zaire glycoproteins are about a 70% match, so some Zaire vaccines or therapies may work against Bundibugyo; remdesivir performed poorly in human Zaire studies, but lab tests suggest stronger activity here. A Global Preparedness Monitoring Board report said preparedness is being outpaced by pandemic risks, geopolitical instability and rapidly evolving information ecosystems after nearly a decade of health emergencies. In this outbreak, the gap between scientific progress and social reality has become decisive.